Request Demo
Last update 25 May 2025
Valsartan/Lercanidipine Hydrochloride
Last update 25 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Lercanidipine/valsartan, Levacalm, Valsartan/lercanidipine |
Target |
Action antagonists, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (01 Jul 2013), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS Registry137862-53-4 |
View All Structures (2)
Related
4
Clinical Trials associated with Valsartan/Lercanidipine HydrochlorideTCTR20241002004
A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Lercanidipine 20 mg Film-coated Tablets and Reference Product (ZANIDIP) in Healthy Thai Volunteers under Fasting Conditions
NCT02415192
A Multicenter, Prospective Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Patient With Essential Hypertension
NCT01928628
A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.
100 Clinical Results associated with Valsartan/Lercanidipine Hydrochloride
Login to view more data
100 Translational Medicine associated with Valsartan/Lercanidipine Hydrochloride
Login to view more data
100 Patents (Medical) associated with Valsartan/Lercanidipine Hydrochloride
Login to view more data
100 Deals associated with Valsartan/Lercanidipine Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Essential Hypertension | South Korea | 01 Jul 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free